SCHEMBL15577403

SCHEMBL15577403

Cc1cc(Nc2nccs2)cc(-c2ccncc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G7 Q13093 1/20 0.47
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
MAPT P10636 4/20 0.46
RAB9A P51151 3/20 0.46
MAPK1 P28482 2/20 0.46
HTT P42858 2/20 0.46
HDAC6 Q9UBN7 1/20 0.46
NPC1 O15118 2/20 0.43
SRC P12931 3/20 0.42
ZAP70 P43403 3/20 0.42
SYK P43405 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.38
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
CDK2 P24941 1/20 0.36
PPIA P62937 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16119591 0.83 PLA2G7 (0.54) PLA2G7MEN1KMT2AMAPTRAB9A
SCHEMBL17397927 0.76 PLA2G7 (0.49) PLA2G7MEN1KMT2AMAPTRAB9A
SCHEMBL4238370 0.74 PLA2G7 (0.60) PLA2G7MEN1KMT2AMAPTRAB9A
SCHEMBL5762561 0.73 PLA2G7 (0.58) PLA2G7MEN1KMT2AMAPTRAB9A
SCHEMBL1883755 0.71 MAPT (0.79) MEN1KMT2AMAPTRAB9AMAPK1
SCHEMBL11996127 0.70 MAPT (0.58) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL15871973 0.70 MAPT (0.58) MEN1KMT2AMAPTRAB9AMAPK1
SCHEMBL12070457 0.70 MAPT (0.58) MEN1KMT2AMAPTRAB9ANPC1
SCHEMBL851128 0.69 PLA2G7 (0.54) PLA2G7MEN1KMT2AMAPTRAB9A
SCHEMBL20529581 0.69 PLA2G7 (0.70) PLA2G7MEN1KMT2AMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3554470-B1 COSMETIC COMPOSITIONS COMPRISING HYALURONIC ACID ELC MAN LLC (US) 2023-07-26 EP disclosed
CN-110381918-B Cosmetic composition ELC 管理有限责任公司 2022-08-30 CN disclosed
US-11291286-B2 Cosmetic compositions with a micro-mesh structure ELC MANAGEMENT LLC (US) 2022-04-05 US disclosed
CN-104797237-B Methods and compositions for improving selective catabolism in cells on the surface of keratin ELC 管理有限责任公司 2020-11-24 CN disclosed
US-20200329844-A1 Cosmetic Compositions ELC MAN LLC (US) 2020-10-22 US disclosed
EP-2941241-B1 METHOD AND COMPOSITIONS FOR IMPROVING SELECTIVE CATABOLYSIS AND VIABILITY IN CELLS OF KERATIN SURFACES ELC MAN LLC (US) 2020-10-21 EP disclosed
CN-111494253-A Methods and compositions for improving selective catabolism and viability in cells on the surface of keratin ELC 管理有限责任公司 2020-08-07 CN disclosed
US-10660420-B2 Cosmetic compositions ELC MANAGEMENT LLC (US) 2020-05-26 US disclosed
EP-3554470-A2 COSMETIC COMPOSITIONS ELC Management LLC (US) 2019-10-23 EP disclosed
EP-3538064-A1 TOPICAL COMPOSITIONS AND METHODS FOR STIMULATING MIR-146A IN SKIN CELLS ELC Management LLC (US) 2019-09-18 EP disclosed
WO-2016144569-A1 METHODS AND COMPOSITIONS FOR TREATING SKIN TO RESOLVE INFLAMMATION AND SCREENING FOR ACTIVES THAT STIMULATE PRO-RESOLUTION PATHWAYS ELC MANAGEMENT LLC (US) 2016-09-15 WO disclosed
EP-2941241-A1 METHOD AND COMPOSITIONS FOR IMPROVING SELECTIVE CATABOLYSIS AND VIABILITY IN CELLS OF KERATIN SURFACES ELC Management LLC (US) 2015-11-11 EP disclosed
US-20150313830-A1 Method And Compositions For Improving Selective Catabolysis And Viability In Cells Of Keratin Surfaces ELC MAN LLC (US) 2015-11-05 US disclosed
CN-104902872-A Methods and compositions for improving selective catabolism and viability in cells on the surface of keratin ELC MAN LLC 2015-09-09 CN disclosed
EP-2897582-A1 METHOD AND COMPOSITIONS FOR IMPROVING SELECTIVE CATABOLYSIS IN CELLS OF KERATIN SURFACES ELC Management LLC (US) 2015-07-29 EP disclosed
CN-104797237-A Methods and compositions for improving selective catabolism in cells on the surface of keratin ELC MAN LLC 2015-07-22 CN disclosed
US-20150071895-A1 Method And Compositions For Improving Selective Catabolysis in Cells Of Keratin Surfaces PERNODET NADINE A (US) 2015-03-12 US disclosed
WO-2014107411-A1 METHOD AND COMPOSITIONS FOR IMPROVING SELECTIVE CATABOLYSIS AND VIABILITY IN CELLS OF KERATIN SURFACES ELC MANAGEMENT LLC (US) 2014-07-10 WO disclosed
US-20140193391-A1 Method And Compositions For Improving Selective Catabolysis And Viability In Cells Of Keratin Surfaces ELC MAN LLC (US) 2014-07-10 US disclosed
WO-2014043009-A1 METHOD AND COMPOSITIONS FOR IMPROVING SELECTIVE CATABOLYSIS IN CELLS OF KERATIN SURFACES ELC MANAGEMENT LLC (US) 2014-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150313830-A1 Method And Compositions For Improving Selective Catabolysis And Viability In Cells Of Keratin Surfaces KRT18, CTSA, UNG PLA2G7 2946/4885MEN1 4832/4885KMT2A 2162/4885
US-10660420-B2 Cosmetic compositions CD44, CUTA, MSH6 PLA2G7 2174/4885MEN1 1503/4885KMT2A 1486/4885
US-20150071895-A1 Method And Compositions For Improving Selective Catabolysis in Cells Of Keratin Surfaces KRT18, ATG7, SQSTM1 PLA2G7 3106/4885MEN1 4563/4885KMT2A 1686/4885
US-20200329844-A1 Cosmetic Compositions CD44, CUTA, MSH6 PLA2G7 2174/4885MEN1 1503/4885KMT2A 1486/4885
US-20140193391-A1 Method And Compositions For Improving Selective Catabolysis And Viability In Cells Of Keratin Surfaces KRT18, BECN1, CTSA PLA2G7 2654/4885MEN1 4543/4885KMT2A 1933/4885
US-11291286-B2 Cosmetic compositions with a micro-mesh structure CD44, CUTA, MSH6 PLA2G7 2338/4885MEN1 1167/4885KMT2A 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.